Sidi Mohamed El Amine Benlazar/X
Sep 12, 2026, 17:43
Sidi Mohamed El Amine Benlazar: CPX-351 and Ruxolitinib in Advanced-Phase Myeloproliferative Neoplasms
Sidi Mohamed El Amine Benlazar, Professor of Hematology, Head of the Hospitalization and Geriatric Unit at the University Hospital of Sidi Bel Abbès, shared a post on X about a recent article by Shivani Handa et al., published in Blood Neoplasia, adding:
“CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study”
Title: CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study
Authors: Shivani Handa, Yazan Madanat, Kelly Pugh, Kaitlyn Dvorak-Kornaus, Qiuhong Zhao, Alice Mims, Kristin Koenig, Andrew Srisuwananukorn, Rachel Cook, Ronan Swords, Uma Borate

Stay updated on all scientific advances with Hemostasis Today.
Alice Mims
Andrew Srisuwananukorn
Blood
Blood Neoplasia
CPX-351
Health
Hematology
Hemostasis
Hemostasis News
Hemostasis Today
Kaitlyn Dvorak-Kornaus
Kelly Pugh
Kristin Koenig
Medicine
myeloproliferative neoplasms
Qiuhong Zhao
Rachel Cook
Ronan Swords
ruxolitinib
Shivani Handa
Sidi Mohamed El Amine Benlazar
Uma Borate
Yazan Madanat
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
-
Sep 12, 2026, 17:49Kalyan Roy: TRAGS – An Emerging Transfusion Safety Concern
-
Sep 12, 2026, 17:48Jason Fung: What Happened to “Statins Save Lives”?
-
Sep 12, 2026, 17:47Eric Topol: Most Supplements and Vitamins Offer Little Proven Benefit
-
Sep 12, 2026, 17:44Manuel Monreal: Clinical Characteristics, Treatment, and Outcomes in Hispanic vs Caucasian Patients With VTE
-
Sep 12, 2026, 17:42Elad Asher: Higher IPF Is Associated with Adverse Outcomes in ICCU